^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Tevimbra (tislelizumab-jsgr) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
China National Medical Products Administration Approves BeiGene’s Tislelizumab for Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Published date:
04/10/2020
Excerpt:
...anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products Administration (NMPA) as a treatment for patients with locally advanced or metastatic urothelial carcinoma (UC) with PD-L1 high expression whose disease progressed during or following platinum-containing chemotherapy...
Source:
Title:
Study on the correlation between the efficacy of tirelizumab in the treatment of advanced urothelial carcinoma and intestinal flora
Excerpt:
...The investigator judges that the patient is not suitable for platinum-based drug therapy or fails first-line therapy and has high expression of PD-L1; 4. ...
Trial ID:
Source:
Title:
Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma
Published date:
11/06/2020
Excerpt:
...efficacy of tislelizumab 200 mg administered intravenously Q3W in patients with locally advanced or metastatic PD‐L1+ UC who progressed during or following platinum‐containing therapy….Figure 4…ORR was found to be 29.4% in patients with PD-L1 >/= 50%
DOI:
10.1111/cas.14681
Trial ID:
